top of page
Soleno Therapeutics
Soleno Therapeutics, Inc. (Soleno) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Our first priority is Prader-Willi syndrome (PWS), a rare and life-threatening neurobehavioral, metabolic, and endocrine disorder characterized by hyperphagia (insatiable hunger), neurocognitive, and behavioral difficulties. We are dedicated to bringing the first approved treatment to individuals with PWS to manage the most burdensome aspects of this devastating disorder. For more information, please visit www.soleno.life.
bottom of page